Aura Biosciences, Inc.
AURANASDAQHealthcareBiotechnology
Regular session
$7.77
−$0.03 · -0.38%
AURA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
30
Expensive
Momentum
49
Neutral
Sentiment
69
Bullish
Risk resilience
48
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteHeadquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Natalie C. Holles
- Listed since
- Oct 29, 2021
- Employees
- 113
Market position
Day range
Current $7.77
52-week range
Current $7.77
- Open
- $7.71
- Previous close
- $7.80
- Volume
- 127.55K
- 0.2× average
- Average volume
- 646.94K
- Average daily volume
- Market cap
- 803.7M USD
- Beta
- 0.4
- Market reference 1
- 50-day average
- $7.1396
- +8.83% above average
- 200-day average
- $6.4952
- +19.63% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 286.7M USD
- P/E (TTM)
- -4.37×
- P/B (TTM)
- 2.34×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.73×
- Earnings yield
- -32.29%
- Free cash flow yield
- -25.91%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -77.56%
- Return on assets
- -62.68%
- Return on invested capital
- -73.10%
Financial health
- Debt / equity
- 0.05×
- Current ratio
- 8.15×
- Altman Z-score
- 12.28
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 1.3M USD | — | — |
| Gross profit | — | — | −1.3M USD | — | — |
| Research and development | 90.3M USD | 73.3M USD | 63.94M USD | 42.24M USD | 25.16M USD |
| Selling, general, and administrative | 22.49M USD | 22.81M USD | 19.76M USD | 18.06M USD | 10.09M USD |
| Operating expenses | 112.79M USD | 96.12M USD | 83.7M USD | 60.3M USD | 35.25M USD |
| Interest income | 6.63M USD | 9.43M USD | 8.59M USD | 1.86M USD | 13K USD |
| Depreciation and amortization | 1.13M USD | 1.22M USD | 1.3M USD | 1.18M USD | 831K USD |
| Operating income | −112.79M USD | −96.12M USD | −84.99M USD | −60.3M USD | −35.25M USD |
| Net income | −106.19M USD | −86.92M USD | −76.41M USD | −58.76M USD | −35.25M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -1.76
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year EPS consensus
- -1.67
- FY2026 · 3 analysts
- Next fiscal-year revenue consensus
- 19.2M USD
- FY2026 · 4 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
8 ratingsAURA news
AURA peers
ETFs holding AURA
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI20.75M0.00%2.3T USD0.03%$376.85-0.37%
iShares Russell 2000 ETFIWM8.94M0.01%81.62B USD0.19%$298.76-0.40%
Vanguard Extended Market ETFVXF7.95M0.01%93.7B USD0.05%$243.82-0.70%
iShares Biotechnology ETFIBB3.72M0.03%10.75B USD0.44%$211.05-1.18%
iShares Russell 2000 Growth ETFIWO3.07M0.02%15.16B USD0.24%$383.52-0.99%
Fidelity Enhanced Small Cap ETFFESM2.43M0.04%6.03B USD0.28%$47.74-0.42%
Vanguard Health Care ETFVHT1.98M0.01%20.9B USD0.09%$327.03-0.21%
Schwab International Small-Cap Equity ETFSCHC1.8M0.03%5.73B USD0.06%$51.145-0.20%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 20.75M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.85-0.37%
iShares Russell 2000 ETFIWM- Market value
- 8.94M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $298.76-0.40%
Vanguard Extended Market ETFVXF- Market value
- 7.95M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.82-0.70%
iShares Biotechnology ETFIBB- Market value
- 3.72M
- Weight
- 0.03%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $211.05-1.18%
iShares Russell 2000 Growth ETFIWO- Market value
- 3.07M
- Weight
- 0.02%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $383.52-0.99%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 2.43M
- Weight
- 0.04%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.74-0.42%
Vanguard Health Care ETFVHT- Market value
- 1.98M
- Weight
- 0.01%
- AUM
- 20.9B USD
- Expense ratio
- 0.09%
- Price / 1D
- $327.03-0.21%
Schwab International Small-Cap Equity ETFSCHC- Market value
- 1.8M
- Weight
- 0.03%
- AUM
- 5.73B USD
- Expense ratio
- 0.06%
- Price / 1D
- $51.145-0.20%
Continue in GoAI
Research AURAresearch.disclaimer